A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
Public ClinicalTrials.gov record NCT04668339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older
Study identification
- NCT ID
- NCT04668339
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 581 participants
Conditions and interventions
Conditions
Interventions
- ARCT-021 single dose priming Biological
- ARCT-021 two lower dose priming Biological
- ARCT-021 two higher dose priming Biological
- Placebo (two doses), priming Biological
- Randomized booster Biological
- Placebo booster Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2021 (Actual)
- Primary completion
- Mar 1, 2022 (Actual)
- Completion
- Mar 1, 2022 (Actual)
- Last update posted
- May 15, 2025
2021 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcturus Investigational Site 103 | Chandler | Arizona | 85224 | — |
| Arcturus Investigational Site 107 | Tucson | Arizona | 85741 | — |
| Arcturus Investigational Site 112 | San Diego | California | 92108 | — |
| Arcturus Investigational Site 104 | Melbourne | Florida | 32934 | — |
| Arcturus Investigational Site 105 | Orlando | Florida | 32806 | — |
| Arcturus Investigational Site 106 | Pinellas Park | Florida | 33781 | — |
| Arcturus Investigational Site 109 | The Villages | Florida | 32162 | — |
| Arcturus Investigational Site 101 | Peoria | Illinois | 61614 | — |
| Arcturus Investigational Site 110 | Rockville | Maryland | 20850 | — |
| Arcturus Investigational Site 102 | Anderson | South Carolina | 29621 | — |
| Arcturus Investigational Site 111 | Austin | Texas | 78705 | — |
| Arcturus Investigational Site 108 | Dallas | Texas | 75234 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04668339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04668339 live on ClinicalTrials.gov.